Feature | February 06, 2007| Kim Phelan

Heart Hospital: Not Skipping a Beat

At George Washington University Hospital, a lead EP doc is pursuing solutions to atrial fibrillation and its many haunting questions.

Dr. Cynthia Tracy, head of Electrophysiology at GWUH, is involved in AFib research and says that better tools can be developed for safely delivering energy to the myocardium for AFib ablation

Dr. Cynthia Tracy, head of Electrophysiology at GWUH, is involved in AFib research and says that better tools can be developed for safely delivering energy to the myocardium for AFib ablation

Status quo is probably not a phrase in Dr. Cynthia Tracy’s professional vocabulary, because, in her daily combat against a disease that’s currently affecting more than two million Americans, good tools and treatment are simply not good enough.

Tracy, M.D., director of Electrophysiology Laboratories at The George Washington University Hospital (GWUH) in Washington, DC, is a leading authority and practitioner in cardiac ablation, a field that is gaining notoriety due to the rapidly expanding diagnoses of atrial fibrillation (AFib). Today, debate has moved centerstage as to whether drug therapy or AFib ablation is the more sound treatment for the disease, which can lead to chronic fatigue, heart failure and stroke. And Dr. Tracy wants to be sure her facility is a part of any advance that will answer questions and remove barriers to providing more people with better disease management.

One such effort is the CABANA trial (Catheter Ablation vs. Antiarrhythmic Drug Therapy for Atrial Fibrillation) spearheaded by Dr. Doug Packer at Mayo Clinic College of Medicine. Dr. Tracy, who attended an investigator’s meeting concerning AFib last fall, says she’s in the process of learning more about CABANA and hopes GWUH will be considered as one of the sites for the trial.

“We have to go back and ask the question, ‘Is AFib ablation a good thing or not?’ ” she said. “Does this change outcomes for patients with atrial fibrillation, because, for instance, the AFFIRM study showed that the outcomes in patients who were allowed to remain in [AFib] with great control in anticoagulation were as good or better than the outcomes of patients who we treated with antiarrhythmic therapy... you have to ask, ‘Are you doing them something good long term? Are you making them live longer?’ We know that we’re making them feel better, but what are we really accomplishing here in terms of altering disease states?”

Accounting for about 35 percent of all arrhythmias, AFib is a condition in which electrical signals that coordinate the muscle of the upper chambers of the heart become rapid and chaotic, resulting in an irregular heart beat, often exceeding 300 beats per minute, according to the Heart Rhythm Society (HRS). According to research last year by HRS, treatment for AFib is inconsistent in this country, and many physicians do not follow or prescribe according to existing guidelines, a deficiency that results in gross under-treatment of those afflicted with the disease — only 25 percent of people with AFib, experts estimate, are receiving appropriate care.

Ablation Consternation
Success rates with AFib catheter ablation are considerably below those for ablation procedures for other types of arrhythmias, says Dr. Tracy — between 80 to 88 percent, she estimated, and even so, more than one procedure may be required to achieve successful AFib ablation.

And there are mysteries aplenty when electrophysiologists are confronted with diagnostic decision-making and interventions.

“It is still an extremely challenging area to figure out what is the best technique to ablate these people,” said Dr. Tracy. “How do you know when you are dealing with something more focal versus something where the entire atrial myocardium has problems?

“What are the best tools for screening patients ahead of time?” she continued. “Are there some markers we can know and determine that it isn’t going to work? How do we define who is a good candidate? How do we define the lesion sets that we should be delivering? How do we assess efficacy with management afterwards? How do we handle anticoagulation? There are just a ton of unanswered questions in that particular area,” Dr. Tracy said.

“Given that AFib is the most common sustained cardiac arrhythmia there is, it is a big deal. If we can can come up with something that can effectively treat a significant portion of these patients, then it is a huge deal.”

That “something” that will lead to better outcomes may lie in robotic technology, Dr. Tracy believes. She cites Hansen as one company that has developed a tool for robotically moving the ablation catheter. Not currently FDA-approved in the U.S., the catheter tool is manipulated with a joystick by an operator who can sit remotely at a desk, Dr. Tracy explained. But issues of safety with the catheter system are still under investigation. (Please see sidebar from Robotics article)

What is commercially available in the present, she notes, is the robotic system sold by Stereotaxis, in which enormous magnets are used to virtually create the image and enable the operator to steer the catheter to the exact location in the myocardium.

“The beauty of the Stereotaxis is that the system’s catheter is like a piece of spaghetti,” she said. “Judging from the data from their studies, it looks like you would have to do something incredibly wrong to perforate with that catheter. I was talking to them and they couldn’t even tell me about any perforations that have ever occurred with their catheter. It’s so flexible. That could possibly be the future of EP.”

Related Content

New Oral Anticoagulant Drugs Associated with Lower Kidney Risks
News | Antiplatelet and Anticoagulation Therapies| December 12, 2017
Mayo Clinic researchers have shown a link between which type of oral anticoagulant a patient takes to prevent a stroke...
Stereotaxis Receives Regulatory Approval of e-Contact Module in Canada
Technology | Ablation Systems| December 08, 2017
December 7, 2017 — Stereotaxis Inc.
New data on the Corvia intra-atrial shunt to treat diastolic heart failure were presented at the recent 2017 American Heart Association (AHA) Scientific Sessions. It was the most popular story in November.

New data on the Corvia intra-atrial shunt to treat diastolic heart failure were presented at the recent 2017 American Heart Association (AHA) Scientific Sessions. It was the most popular story in November.

Feature | December 06, 2017 | Dave Fornell
Here is the list of the most popular articles and videos on the Diagnostic and Interventional Cardiology (DAIC) magaz
Research team (left to right) Abdul Wase M.D. (principal ivestigator), Marina Brown R.N., Ken Shneider, Thein Aung M.D., Matt Clark, Dawn Hunt and Kimberle Evans R.N., with a Tesla car at Good Samaritan Hospital Dayton, Ohio.  Image courtesy of Joe Carfora.

Research team (left to right) Abdul Wase M.D. (principal ivestigator), Marina Brown R.N., Ken Shneider, Thein Aung M.D., Matt Clark, Dawn Hunt and Kimberle Evans R.N., with a Tesla car at Good Samaritan Hospital Dayton, Ohio. 
Image courtesy of Joe Carfora.

News | November 25, 2017
November 25, 2017 — Sitting in, or standing close to the charging port of a Tesla electric vehicle did not trigger a
Mexican Doctors Safely Reuse Donated Pacemakers After Sterilization
News | Pacemakers| November 10, 2017
Mexican doctors have safely reused donated pacemakers after sterilization, shows a study presented at the 30th Mexican...
Acutus dipole density EP mapping for ablation procedures.

The FDA recently cleared high-speed Acutus Medical's AcQMap High Resolution image and mapping system and the AcQMap 3-D Imaging and Mapping Catheter.  detects and displays both standard voltage-based and higher resolution dipole density (charge-source) maps. The system combines ultrasound anatomy construction with an ability to map the electrical-conduction of each heartbeat to identify complex arrhythmias across the entire atrial chamber. Following each ablation treatment, the heart can be re-mapped in seconds to continually visualize any changes from the prior mapping.

 

 

Feature | Atrial Fibrillation| November 07, 2017
November 7, 2017 — Here is an aggregated list of articles detailing the latest clinical data and new device technolog
The Abbott/St. Jude Confirm RX implantable cardiac monitor (ICM) is the first ICM that is compatible with patients' smartphones to eliminate the need for a bedside base unit monitor to transfer data to physicians. Its FDA clearance was in October 2017.

The Abbott/St. Jude Confirm RX implantable cardiac monitor (ICM) is the first ICM that is compatible with patients' smartphones to eliminate the need for a bedside base unit monitor to transfer data to physicians. Its FDA clearance was the No. 1 most popular article on DAIC in October.

Feature | November 03, 2017 | Dave Fornell
November 3, 2017 — Here is the list of the most popular articles and videos on the Diagnostic and Interventional Card
Societies Detail Treatment for Patients With Ventricular Arrhythmias
News | EP Lab| October 30, 2017
The American College of Cardiology, along with the American Heart Association and the Heart Rhythm Society, published...
Videos | EP Mapping and Imaging Systems| October 24, 2017
This video, provided by Acutus Medical, demonstrates a patient case showing the use of the AcQMap high-resolution ele
Acutus Medical Receives FDA Clearance for AcQMap Cardiac Mapping Technology
Technology | EP Mapping and Imaging Systems| October 24, 2017
Acutus Medical announced that the U.S. Food and Drug Administration (FDA) has cleared the AcQMap High Resolution...
Overlay Init